Navigation Links
NCP-2 External Counterpulsation Device

ProductsNCP-2 External Counterpulsation Device
Company Applied Cardiac Systems, Inc
Item NCP-2 External Counterpulsation Device
Features The ACS Treatment Report offers:
  • Review of patients progress
  • Display of Fifteen and Thirty Minute Full Disclosure (ECG, Cuff Inflation and Deflation Timing, Arterial Pressure Waveform)
  • Ability to monitor, record, and print ECG and clinically relevant episodes
  • Ability to monitor, record, and print ECG and clinically relevant episodes
  • Assess staff interaction through detailed trending reports
NCP-2 (an enhanced NCP-1 device) features:
  • Vacuum Pump Technology allows cuffs to fully inflate and deflate with every cardiac cycle to increase vascular recoil and minimizing patient slamming
  • Operators can adjust platform levels for patient comfort and compliance. The raised edges of the treatment platform provide increased stability for your CHF and angina patients
  • Control station is designed with mobility to accommodate most ECP treatment rooms
  • First ever ECP Treatment Report is displayed on a large format LCD screen for ease of operation.
Description With the launch of the NCP-2, ACS proudly introduces full disclosure to ECP Therapy. ACS has given physicians more tools for assessing the administration of ECP therapy through the first and only complete ECP Treatment Report. The ACS Treatment Report is a patent-pending, proprietary software program that allows both physicians and therapists to review patient progress throughout the course of ECP therapy. At the same time, therapists can now generate a clinically relevant treatment report.
Info Applied Cardiac Systems, Inc
Customer Service: (800) 423-2929
Web site: http://www.acsholter.com

Related medicine products :

1. The External Neurological Drainage System
2. Monitorr ICP External CSF Drainage and Monitoring System
3. Monitorr ICP External CSF Drainage System
4. EDS 3 CSF External Drainage System
5. Lumbar External Drainage System (LED)
6. External Ventricular Drainage (EVD)
7. Becker External Drainage and Monitoring System
8. Dual-Chamber Model 5388 External (Temporary) Pulse Generator
9. Single-Chamber Model 5348 External (Temporary) Pulse Generator
10. The Hoffmann® II For External Fixation
11. XCaliber External Fixator
The Multi-Purpose Stand Magnifier is the most versatile stand magnifier. The stand has multiple configurations allowing for all situations where hands-free magnification is needed.
Contour design eyelid implants.
Bausch & Lomb magnifiers incorporates precision optics and patented ergonomic designs for increased clarity and comfort during use.
Ultra Thin Sheet. Medpor Sheets are commonly used for orbital floor reconstruction and other craniofacial applications.
Medicine Products:
(Date:8/8/2008)...wswire-USNewswire/ National Hospice and,Palliative... honor the,recipients of the 2008 Circle of Life A...ion in end-of-life care and highlights programs th... Award recipients were announced July 25 at the A...n Diego. This year,s Award winners are:, -- Pain ...
(Date:8/7/2008)... elevated levels of prostate-specific antigen (PSA... for prostate cancer -- may be biased against obes.... And this bias may be creating more aggressive c...ccording to a new study led by investigators in th...airs (VA) Medical Center. , "We know that obese...
(Date:8/7/2008)...sting, could ID millions who don,t know they have... News) -- A widely used test to monitor blood suga...fy millions of people with undetected diabetes, ac...m of experts. , The hemoglobin A1c test (HbA1c... exposed to in the previous 120 days, the average ...
(Date:8/7/2008)...Newswire-USNewswire/ -- Vapotherm, the,global lead...ved 510(k),clearance from the Food and Drug Admini...igh flow humidification system to integrate gas,bl... into one device for,the optimal conditioning of n...ducts are currently used in neonatal, pediatric an...
Breaking Medicine News(10 mins):Health News:Circle of Life Awards Recognize Innovative End-of-Life Care Providers 2Health News:Circle of Life Awards Recognize Innovative End-of-Life Care Providers 3Health News:PSA screening may be biased against obese men, leading to more aggressive cancers 2Health News:Blood Sugar Test May Also Aid Diabetes Detection 2Health News:Vapotherm(R) Precision Flow(TM) Receives FDA 510(k) Clearance 2
... child obesity is severe like never before. The pr...lieve as a study from Tufts University this month ... most definitely prologue. // ''It's quite astoun...to wait," said Vivien Morris, a Boston Medical Cen...
...w that the incidence of breast cancer is rapidly i...of the cervix as the number one cancer in our majo...nd cancer in India.// The number of breast cancer...ve reached 1.2 million worldwide. Snacking, fatty...
...om Harvard Medical School had discovered a kind of...owth of new lymph vessels in the eyes. These new l...f there being any wounds. // The discovery of thi...ed in the September 2005 Journal of Clinical Inves...
...ys been a quest regarding the treatment of AIDS/HI...ite the initiation of a global research, AIDS stil...oximately five percent of patients with HIV, or hu...elop AIDS, or do so very slowly.// Past research ...
Other Medicine News:Health News:Early Awareness About Weight Management Needed To Tackle Lifelong Obesity 2Health News:Lymph Cell Growth In Eyes Related To Macrophages 2Health News:Study holds promise for new way to fight HIV 2
(Date:8/5/2008)...l to be held on Wednesday, August 6, 2008 at 8:00 ..., Aug. 5 /- Isolagen(TM), I...efficacy and safety results from two,pivotal, Phas...006) of the,Isolagen Therapy(TM) for the treatment...ducted under an FDA Special Protocol Assessment (S...
(Date:8/5/2008)...ines efficacy and safety of once-daily TMC278 in ...-, MEXICO CITY, Aug. 5 /- New phase ...s additional information on the safety and,efficac...onal,non-nucleoside reverse transcriptase inhibito...reatment-naive adults. These findings were,present...
(Date:8/5/2008)...nned for advanced or recurrent solid tumors, PRIN...rex, Inc.,(Nasdaq: MEDX ) announced today the all...(IND) filed with the U.S. Food & Drug Administrati...ts with selected advanced or recurrent,solid tumor...n-small cell,lung cancer or epithelial ovarian can...
(Date:8/5/2008)...J., Aug. 5 /- MicroDose Technologies,...inical milestone in its,collaboration with Merck &...hieved, triggering the first payment under the glo...nhaler (DPI) technology announced in March,2008. T... Phase I clinical,study of an investigational comp...
Breaking Medicine Technology:Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant 2Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant 3Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant 4Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant 5Ninety-Six Week Data on Tibotec Investigational NNRTI, TMC278, Presented at AIDS 2008 2Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105 2Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105 3MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc. 2Intel Co Founder Andrew S Grove Dedicates Portion of His Estate Up to 2440 Million to Michael J Fox Foundation 9422 1Intel Co Founder Andrew S Grove Dedicates Portion of His Estate Up to 2440 Million to Michael J Fox Foundation 9422 2Intel Co Founder Andrew S Grove Dedicates Portion of His Estate Up to 2440 Million to Michael J Fox Foundation 9422 3BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J Simon M D as Interim Chief Medical Officer To Meet Growing Product De 2552 1BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J Simon M D as Interim Chief Medical Officer To Meet Growing Product De 2552 2BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J Simon M D as Interim Chief Medical Officer To Meet Growing Product De 2552 3BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J Simon M D as Interim Chief Medical Officer To Meet Growing Product De 2552 4Memantine and Alzheimers disease 9416 1Memantine and Alzheimers disease 9416 2Memantine and Alzheimers disease 9416 3Priming Heart Before an Attack Could Limit Damage 9413 1Priming Heart Before an Attack Could Limit Damage 9413 2Priming Heart Before an Attack Could Limit Damage 9413 3
...agonist shown to be therapeutically effective in a...PENHAGEN, 18 April 2007 - Santaris Pharma, the Dan...s, yesterday,presented encouraging data at the Ame...ng in Los Angeles, showing that SPC2996, the,Compa...ctive in a,preclinical model of human Chronic Lymp...
...Calif., April 18, 2007 /PRNewswire-FirstCall/ -- K...linical data on its,proprietary nuclear export inh...ting and long-lasting anticancer activity with a,h... xenograft,cancer models. , Kosan,s NEIs are poten..., essential protein that exports key regulatory pr...
Other Medicine Technology:Santaris Pharma presents positive preclinical data on SPC2996 at,the American Association for Cancer Research 2Santaris Pharma presents positive preclinical data on SPC2996 at,the American Association for Cancer Research 3Santaris Pharma presents positive preclinical data on SPC2996 at,the American Association for Cancer Research 4Santaris Pharma presents positive preclinical data on SPC2996 at,the American Association for Cancer Research 5Santaris Pharma presents positive preclinical data on SPC2996 at,the American Association for Cancer Research 6Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel,Anticancer Agents, at AACR 2Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel,Anticancer Agents, at AACR 3Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel,Anticancer Agents, at AACR 4